NZ772814A - ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - Google Patents
ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOFInfo
- Publication number
- NZ772814A NZ772814A NZ772814A NZ77281417A NZ772814A NZ 772814 A NZ772814 A NZ 772814A NZ 772814 A NZ772814 A NZ 772814A NZ 77281417 A NZ77281417 A NZ 77281417A NZ 772814 A NZ772814 A NZ 772814A
- Authority
- NZ
- New Zealand
- Prior art keywords
- patient
- n3pglu
- antibody
- medicament
- dose
- Prior art date
Links
Abstract
The invention is directed to a short term induction treatment with anti-N3pGlu Aß antibodies of a disease characterized by deposition of Aß in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu Aß antibody for a period of 6 months or less.
Claims (15)
1. Use of an anti-N3pGlu Amyloid ß (Aß) antibody for the manufacture of a medicament for the treatment of Alzheimer’s disease (AD) in a human patient in need thereof wherein the 5 medicament comprises a dose of 10 mg/kg or 20 mg/kg of the anti-N3pGlu Aß antibody, wherein the medicament is to be administered once every four weeks for a period of 16 to 72 weeks to the patient, and wherein the anti-N3pGlu Aß antibody has a light chain of
2. SEQ ID NO: 28 and a heavy chain of SEQ ID NO: 29. 10 2. The use of claim 1, wherein the patient is suffering from preclinical AD, prodromal AD, mild AD, moderate AD, or severe AD.
3. The use of claim 2, wherein the patient is suffering from preclinical AD. 15
4. The use of claim 2, wherein the patient is suffering from prodromal AD.
5. The use of claim 1, wherein the patient carries one or two APOE e4 alleles.
6. The use of claim 1, wherein the medicament comprising a dose of 10 mg/kg of the anti- 20 N3pGlu Aß antibody is to be administered to the patient once every 4 weeks.
7. The use of claim 6, wherein the medicament comprises a dose of 700 mg of the anti- N3pGlu Aß antibody.
8. The use of claim 1, wherein the medicament comprising the dose of 20 mg/kg of the anti- N3pGlu Aß antibody is to be administered to the patient once every 4 weeks.
9. The use of claim 1, wherein the medicament is to be administered intravenously to the 30 patient.
10. The use of claim 1, wherein the medicament causes reduction in Aß deposits in the brain of the patient. 35
11. The use of claim 1, wherein the medicament causes slowing of cognitive decline in the patient.
12. The use of claim 1, wherein the mean reduction in amyloid beta after 3 doses of 10 mg/kg is from -12 CL to -39 CL. 5
13. The use of claim 1, wherein the Aß deposits in the brain of the patient are reduced by 40- 50% within 6 months post treatment.
14. The use of claim 1, wherein the reduction of Aß deposits in the brain of the patient is sustained for a period of at least 18 months after the last dose of the anti-N3pGlu Aß 10 antibody.
15. The use of claim 1, wherein the patient does not suffer from cerebral vasogenic edema or microhemorrhage upon administration of the anti-N3pGlu Aß antibody. 11394637_1
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ772814A true NZ772814A (en) | 2025-01-31 |
| NZ772814B2 NZ772814B2 (en) | 2025-05-01 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017291414B2 (en) | Anti-N3pGLu amyloid beta peptide antibodies and uses thereof | |
| JP2009529502A5 (en) | ||
| MX2014002459A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. | |
| BR112014027010A2 (en) | use of high dose laquinimod for treatment of multiple sclerosis | |
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112014004741A2 (en) | at least one chemical entity; pharmaceutical composition; use of a therapeutically effective amount of at least one chemical entity; packaged pharmaceutical composition | |
| RU2015134581A (en) | NITROXIL DONORS WITH IMPROVED THERAPEUTIC INDEX | |
| Jairath et al. | P115 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate-to-severe Crohn’s disease: results from phase 3 VIVID 1 study | |
| JP2016505050A5 (en) | ||
| JP2019507786A5 (en) | ||
| Pistono et al. | What’s new about oral treatments in Multiple Sclerosis? Immunogenetics still under question | |
| JP2016528171A5 (en) | ||
| NZ772814B2 (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| NZ772814A (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| JP2019535830A5 (en) | ||
| JP2018529747A5 (en) | ||
| JP2020503318A5 (en) | ||
| CN112437661A (en) | Use of benzoic acid or a salt thereof for preventing or treating anti-N-methyl-D-aspartate receptor encephalitis | |
| US20240358726A1 (en) | Specific therapeutic medical marijuana doses for stress and pain | |
| RU2021103424A (en) | METHODS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | |
| CN104826108A (en) | Application of immunoglobulin to manufacturing medicine for treating erythroderma psoriaticum | |
| HK40041658A (en) | Benzoic acid or a salt thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis | |
| NZ773583B2 (en) | Methods of treating psoriasis | |
| Walker et al. | Post-streptococcal neuropsychiatric movement disorders or Sydenham's chorea spectrum disorder: an update on management: more about... paediatric neurology | |
| Osuagwu | Methylprednisolone/methylprednisolone sodium succinate |